Two double-blinded, randomized, comparative trials of 4 Human Immunodeficiency Virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS clinical trials groups 209 and 214

Journal of Infectious Diseases

Volumn 182, Issue 5, 2000, Pages 1357-1364

  Schooley, Robert T ^a   Spino, Cathie ^b,o   Kuritzkes, Daniel ^a   Walker, Bruce D ^c   Valentine, Fred T ^d   Hirsch, Martin S ^c   Cooney, Elizabeth ^e   Friedland, Gerald ^d   Kundu, Smriti ^f   Merigan, Thomas C ^g   McElrath, M Juliana ^f   Collier, Ann ^f   Plaeger, Susan ^h,m   Mitsuyasu, Ronald ^h   Kahn, James ⁱ   Haslett, Patrick ^d   Uherova, Patricia ^a,n   DeGruttola, Victor ^b   Chiu, Simon ^b   Zhang, Bin ^b   Jones, Gayle ^b,q   Bell, Dawn ^l,m   Ketter, Nzeera ^m   Twadell, Thomas ^j   Chernoff, David ^k   Rosandich, Mary ^a,p   Clax, Pamela ^l   Pattishall, Kathryn ^r   Betensky, Rebecca ^b   Coughlin, Kristine ^q   McFarland, Jessica ^l   Rios, V Miles ^j   Purdue, Lynette ^m   Ray, M Graham ^a   more..

^a UNIVERSITY OF COLORADO   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j GENENTECH INC   (United States)

^k NOVARTIS PHARMA AG   (Switzerland)

^l SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^m NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁿ UNIVERSITY OF MICHIGAN   (United States)

^o PFIZER INC   (United States)

^p PPD Pharmaco Corporation   (United States)

^q FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^r GLAXOSMITHKLINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT VACCINE; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; MALE; RNA, VIRAL; VIRAL ENVELOPE PROTEINS;

EID: 0033790862     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315860     Document Type: Article

References (29)

1. Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes
2. + cells: Evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms
3. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
4. Cytotoxic T cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection
5. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
6. HIV-specific cellular and humoral immune responses in primary HW infection
7. + lymphocytes
8. + T cell responses associated with control of viremia
9. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research
10. Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection
11. A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with ≥400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137)
12. Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells
13. Safety and immunogenicity of REMUNE in HIV-infected Thai subjects
14. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
15. + T cell homeostasis and function in advanced HIV disease
16. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS Clinical Trials Group Protocol 315
17. Effects of HAART plus an inactivated HIV immunogen on lymphoproliferative responses (LPR) to HIV antigens
18. HIV-specific cytotoxic T lymphocytes in seropositive individuals
19. High frequency of gag- and envelope-specific cytotoxic T lymphocyte precursors in children and vertically acquired human immunodeficiency virus type 1 infection
20. Safety and immunogenicity of genetically engineered human immunodeficiency virus vaccine
21. Clinical and immunological responses to human immunodeficiency virus (HIV) type 1 SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers
22. Induction of HIV-1 neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-IIIB rgp120 subunit vaccine
23. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network
24. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus, type 1 candidate vaccine, in combination with a novel adjuvant, MTP-DE/MF59. AIDS Vaccine Evaluation Grou
25. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: Recombinant glycoprotein (rgp) 120: A randomized double-blind trial
26. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
27. + T cells using an ELISPOT assay
28. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinaat gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group
29. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response